- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
- Sage Therapeutics to Present at Upcoming March Investor Conferences
More ▼
Key statistics
On Wednesday, SAGE Therapeutics Inc (SAGE:NMQ) closed at 11.71, 7.23% above its 52-week low of 10.92, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.32 |
---|---|
High | 12.58 |
Low | 11.69 |
Bid | 11.68 |
Offer | 12.05 |
Previous close | 11.99 |
Average volume | 919.68k |
---|---|
Shares outstanding | 60.18m |
Free float | 52.68m |
P/E (TTM) | -- |
Market cap | 721.58m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of May 15 2024 21:00 BST.
More ▼